Download this Case Study to Learn More
Early-phase trials are often delayed by rigid manufacturing models, fixed-dose formats, and limited API availability. In this case study, explore how a clinical-stage European biotech partnered with Catalent to complete Phase 1 trials in just 30 weeks using Catalent’s Xpress Pharmaceutics on-demand manufacturing platform. By integrating lipid-based formulation development, adaptive study design, and extemporaneous softgel production at the clinical site, Catalent enabled flexible dose escalation across a 75-fold range, while conserving API and minimizing manufacturing time. With MHRA approval and strong pharmacokinetic results, this agile approach outperformed conventional models, reduced costs by 38%, and helped the sponsor stay on track to clinical milestones.
Offered Free by: Catalent Pharma Solutions
See All Resources from: Catalent Pharma Solutions
Thank you
This download should complete shortly. If the resource doesn't automatically download, please, click here.
Thank you
This download should complete shortly. If the resource doesn't automatically download, please, click here.





